Opinion|Videos|July 26, 2024
Future of Dry Eye Management
Author(s)Alice Epitropoulos, MD, Laura M. Periman, MD
Dry eye experts discuss the future of dry eye management.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- How do you incorporate these new therapies into your practice? What has been your experience with these new options?
- How are these new therapies impacting the time it takes for patients to experience symptom relief?
- When do you consider combining therapies for dry eye?
- What are some of your preferred algorithms?
- What does the future of dry eye management look like? What upcoming advancements are you most excited about?
Advertisement
Related to this article
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
Dry eye cases rise with heavy screen use and younger patients; learn modern workups spotlighting MGD, etiology-driven treatments, and collaborative care reshaping outcomes.
Patients with polyendocrine metabolic ovarian syndrome have higher ocular disease prevalence.
Optometrist–ophthalmologist co-management targets dry eye early, improves cataract and refractive surgery satisfaction, and uses advanced diagnostics and treatments for healthier ocular surfaces.
Their conversation covers a holistic, cross-specialty approach to ocular surface disease and the unmet need driving a new model of dry eye care in Ireland.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Retinal imaging as a window into atrial fibrillation
2
First patient dosed in phase 3 NPI-001 trial for Usher syndrome RP
3
OCT-980 receives FDA orphan drug designation for retinitis pigmentosa
4
Johnson & Johnson spotlights contrast data, 1 million TECNIS implants, and SmartLOAD delivery
5